Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies

Over the last several years, there has been considerable progress in the treatment of cancer using gene modified adoptive T cell therapies. Two approaches have been used, one involving the introduction of a conventional αβ T cell receptor (TCR) against a pepMHC cancer antigen, and the second involving introduction of a chimeric antigen receptor (CAR) consisting of a single-chain antibody as an Fv fragment linked to transmembrane and signaling domains. In this review, we focus on one aspect of TCR-mediated adoptive T cell therapies, the impact of the affinity of the αβ TCR for the pepMHC cancer antigen on both efficacy and specificity. We discuss the advantages of higher-affinity TCRs in mediating potent activity of CD4 T cells. This is balanced with the potential disadvantage of higher-affinity TCRs in mediating greater self-reactivity against a wider range of structurally similar antigenic peptides, especially in synergy with the CD8 co-receptor. Both TCR affinity and target selection will influence potential safety issues. We suggest pre-clinical strategies that might be used to examine each TCR for possible on-target and off-target side effects due to self-reactivities, and to adjust TCR affinities accordingly.

[1]  Robert Maile,et al.  CD8+ T Cell Activation Is Governed by TCR-Peptide/MHC Affinity, Not Dissociation Rate1 , 2007, The Journal of Immunology.

[2]  R. Debets,et al.  Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. , 2005, Gene therapy.

[3]  F. Marincola,et al.  New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer , 2012, Journal of Translational Medicine.

[4]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[5]  P. A. Peterson,et al.  Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. , 1998, Immunity.

[6]  H. Shiku,et al.  Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. , 2011, Blood.

[7]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[8]  Z. Berneman,et al.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. , 2012, The oncologist.

[9]  T. Schumacher,et al.  Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function , 2010, The Journal of Immunology.

[10]  Cheng Zhu,et al.  The kinetics of two dimensional TCR and pMHC interactions determine T cell responsiveness , 2010, Nature.

[11]  D. Kranz,et al.  Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  A. Ribas,et al.  MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. , 2010, Clinical immunology.

[13]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[14]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[15]  H. Schreiber,et al.  Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. , 2005, Cancer immunity.

[16]  Evan W. Newell,et al.  TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity , 2010, Nature.

[17]  A. Sewell,et al.  T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. , 2008, Molecular immunology.

[18]  R. J. Cohen,et al.  Promiscuous binding of extracellular peptides to cell surface class I MHC protein , 2012, Proceedings of the National Academy of Sciences.

[19]  Stuart M. Brown,et al.  Rare, structurally homologous self-peptides promote thymocyte positive selection. , 2002, Immunity.

[20]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[21]  Thomas M Green,et al.  A public genome-scale lentiviral expression library of human ORFs , 2011, Nature Methods.

[22]  D. Fremont,et al.  High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. , 1998, Immunity.

[23]  B. Jakobsen,et al.  Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. , 2011, Blood.

[24]  S. Rosenberg,et al.  T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy , 2013, Journal of Immunotherapy for Cancer.

[25]  G. Plautz,et al.  Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. , 2007, Blood.

[26]  A. Jochemsen,et al.  WT1 proteins: functions in growth and differentiation. , 2001, Gene.

[27]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[28]  Pedro Romero,et al.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.

[29]  Thomas M. Schmitt,et al.  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. , 2013, Blood.

[30]  T. Moore,et al.  Human ORFeome version 1.1: a platform for reverse proteomics. , 2004, Genome research.

[31]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[32]  S. Fujita,et al.  HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. , 2000, Blood.

[33]  David M. Kranz,et al.  Positive and negative selection of an antigen receptor on T cells in transgenic mice , 1988, Nature.

[34]  D. Hart,et al.  Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice , 2010, Haematologica.

[35]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[36]  D. Baltimore,et al.  CD4+CD25− T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model1 , 2008, The Journal of Immunology.

[37]  M. Nishimura,et al.  Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. , 2005, Cancer research.

[38]  David M Kranz,et al.  Display, engineering, and applications of antigen-specific T cell receptors. , 2007, Biomolecular engineering.

[39]  J. Wargo,et al.  A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer , 2011, The Journal of Immunology.

[40]  J. Melenhorst,et al.  Allogeneic HLA-A*02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity , 2011, The Journal of Immunology.

[41]  A. Sewell,et al.  The molecular determinants of CD8 co‐receptor function , 2012, Immunology.

[42]  A. Sewell,et al.  Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties* , 2007, Journal of Biological Chemistry.

[43]  B. Baker,et al.  TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms , 2011, The Journal of Immunology.

[44]  T. Jacks,et al.  Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. , 2011, Cancer cell.

[45]  A. Gaiger,et al.  WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies , 2003, Leukemia.

[46]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[47]  D. Kranz,et al.  T‐cell receptor binding affinities and kinetics: impact on T‐cell activity and specificity , 2009, Immunology.

[48]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[49]  S. Jameson,et al.  The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. , 2001, Immunity.

[50]  Todd M. Allen,et al.  Effects of thymic selection of the T cell repertoire on HLA-class I associated control of HIV infection , 2010, Nature.

[51]  Q. Yi.  Novel Immunotherapies , 2009, Cancer journal.

[52]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[53]  S. Barry,et al.  A High-Throughput Platform for Lentiviral Overexpression Screening of the Human ORFeome , 2011, PloS one.

[54]  L. Pease,et al.  A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity , 1996, The Journal of experimental medicine.

[55]  A. Lanzavecchia,et al.  Serial triggering of many T-cell receptors by a few peptide–MHC complexes , 1995, Nature.

[56]  P. Allen,et al.  The Study of High-Affinity TCRs Reveals Duality in T Cell Recognition of Antigen: Specificity and Degeneracy1 , 2006, The Journal of Immunology.

[57]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[58]  Yi Li,et al.  High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 , 2007, The Journal of Immunology.

[59]  D. Kranz,et al.  Cd8− T Cell Transfectants That Express a High Affinity T Cell Receptor Exhibit Enhanced Peptide-Dependent Activation , 2001, The Journal of experimental medicine.

[60]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[61]  B K Jakobsen,et al.  T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. , 1999, Immunity.

[62]  T. Schumacher,et al.  Generation of T Cell Help through a MHC Class I-Restricted TCR1 , 2006, The Journal of Immunology.

[63]  Magdalini Moutaftsi,et al.  Correlates of protection efficacy induced by vaccinia virus‐specific CD8+ T‐cell epitopes in the murine intranasal challenge model , 2009, European journal of immunology.

[64]  T. Waldmann,et al.  IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis , 2008, Proceedings of the National Academy of Sciences.

[65]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[66]  B. Jakobsen,et al.  Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies , 2012, European journal of immunology.

[67]  John Sidney,et al.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. , 2013, Cancer cell.

[68]  L R Pease,et al.  Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[69]  WT 1 proteins : functions in growth and differentiation , 2001 .

[70]  L. Pease,et al.  Degenerate recognition of alloantigenic peptides on a positive-selecting class I molecule. , 1998, Journal of immunology.

[71]  Steven A. Rosenberg,et al.  Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.

[72]  D. Kranz,et al.  Cutting Edge: Inhibitory Effects of CD4 and CD8 on T Cell Activation Induced by High-Affinity Noncognate Ligands1 , 2009, The Journal of Immunology.

[73]  D. Price,et al.  A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.

[74]  Jianzhu Chen,et al.  A model T-cell receptor system for studying memory T-cell development. , 2003, Microbes and infection.

[75]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[76]  Christina Meyer,et al.  T cell antigen recognition at the cell membrane. , 2012, Molecular immunology.

[77]  Srinivas Devadas,et al.  CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery , 2010, Proceedings of the National Academy of Sciences.

[78]  S. Rosenberg,et al.  Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen , 2004, Journal of immunotherapy.

[79]  T. Blankenstein,et al.  Tumor Rejection by Disturbing Tumor Stroma Cell Interactions , 2001, The Journal of experimental medicine.

[80]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[81]  B. Baker,et al.  Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. , 2009, Molecular immunology.

[82]  P. A. Peterson,et al.  CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes , 1996, Nature.

[83]  V. Zoete,et al.  MM–GBSA binding free energy decomposition and T cell receptor engineering , 2010, Journal of molecular recognition : JMR.

[84]  T. McKeithan,et al.  Kinetic proofreading in T-cell receptor signal transduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Schøller,et al.  Evidence that the Density of Self Peptide-MHC Ligands Regulates T-Cell Receptor Signaling , 2012, PloS one.

[86]  A. Biondi,et al.  Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. , 2012, Human gene therapy methods.

[87]  M. Aljurf,et al.  Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue , 2009, Leukemia & lymphoma.

[88]  N. Restifo,et al.  Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.

[89]  Meir Glick,et al.  Stable, soluble T-cell receptor molecules for crystallization and therapeutics. , 2003, Protein engineering.

[90]  R. Debets,et al.  Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α , 2005, Gene Therapy.

[91]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[92]  A. Sewell,et al.  Peptide length determines the outcome of TCR/peptide-MHCI engagement. , 2013, Blood.

[93]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[94]  H. Eisen,et al.  Specificity and degeneracy in antigen recognition: yin and yang in the immune system. , 2001, Annual review of immunology.

[95]  J. Goldman,et al.  Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients , 2003, Transplantation.

[96]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[97]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[98]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[99]  A. Iwasaki,et al.  CTL mobilization to virus-infected tissue requires CD4+ T cell help , 2009, Nature.

[100]  E. Palmer,et al.  A constant affinity threshold for T cell tolerance , 2007, The Journal of experimental medicine.

[101]  T. Yoshimoto,et al.  Immunogenic variation between multiple HLA-A*0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes. , 2006, Viral immunology.

[102]  H. Eisen,et al.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.

[103]  Alexis M. Kalergis,et al.  Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex , 2001, Nature Immunology.

[104]  B. Engels,et al.  Articles on similar topics can be found in the following Blood collections Gene Therapy (517 articles) , 2005 .

[105]  D. Kranz,et al.  MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR , 2013, Cancer Immunology, Immunotherapy.

[106]  D. Kranz,et al.  T cell receptor engineering. , 2012, Methods in enzymology.

[107]  Alessandro Sette,et al.  Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.

[108]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[109]  Zhiping Weng,et al.  Structure‐based design of a T‐cell receptor leads to nearly 100‐fold improvement in binding affinity for pepMHC , 2009, Proteins.

[110]  V. Cerundolo,et al.  Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 , 2000, The Journal of Immunology.

[111]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[112]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[113]  K. Garcia,et al.  A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. , 2000, Immunity.

[114]  S. Jameson,et al.  Central tolerance: learning self-control in the thymus , 2005, Nature Reviews Immunology.

[115]  S. Xue,et al.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[116]  David M Kranz,et al.  Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[117]  T. Beddoe,et al.  Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue* , 2004, Journal of Biological Chemistry.

[118]  Yi Li,et al.  Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.

[119]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[120]  D. Scheinberg,et al.  Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein , 2006, Leukemia.

[121]  Robyn L. Stanfield,et al.  An αβ T Cell Receptor Structure at 2.5 Å and Its Orientation in the TCR-MHC Complex , 1996, Science.

[122]  D. Speiser,et al.  CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[123]  David M. Kranz,et al.  Distinct CDR3 Conformations in TCRs Determine the Level of Cross-Reactivity for Diverse Antigens, but Not the Docking Orientation1 , 2008, The Journal of Immunology.

[124]  R. J. Cohen,et al.  Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. , 1994, Immunity.

[125]  Zuqiang Liu,et al.  Potent Tumor-Specific Protection Ignited by Adoptively Transferred CD4+ T Cells1 , 2008, The Journal of Immunology.

[126]  Yi Li,et al.  Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide‐MHC without increasing apparent cross‐reactivity , 2006, Protein science : a publication of the Protein Society.

[127]  G. Gao,et al.  Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. , 2002, Trends in immunology.

[128]  Daniel Coombs,et al.  Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time , 2010, Immunity.

[129]  Thomas M. Schmitt,et al.  Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients , 2013, Science Translational Medicine.

[130]  P. Allen,et al.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. , 1991, Science.

[131]  H. Ikeda,et al.  Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. , 2005, Blood.

[132]  Thomas M. Schmitt,et al.  Opposite Effects of Endogenous Peptide–MHC Class I on T Cell Activity in the Presence and Absence of CD8 , 2011, The Journal of Immunology.

[133]  S. Rosenberg,et al.  Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.

[134]  Hedi Mattoussi,et al.  Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response , 2006, Proceedings of the National Academy of Sciences.

[135]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[136]  Philippa Marrack,et al.  Evolutionarily conserved amino acids that control TCR-MHC interaction. , 2008, Annual review of immunology.

[137]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Andrew Sewell,et al.  Structural and kinetic basis for heightened immunogenicity of T cell vaccines , 2005, The Journal of experimental medicine.

[139]  Yvonne McGrath,et al.  Monoclonal TCR-redirected tumor cell killing , 2012, Nature Medicine.

[140]  K. Garcia,et al.  Different Strategies Adopted by Kb and Ld to Generate T Cell Specificity Directed against Their Respective Bound Peptides* , 2009, The Journal of Biological Chemistry.

[141]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[142]  K D Wittrup,et al.  In vitro evolution of a T cell receptor with high affinity for peptide/MHC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[143]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[144]  S. Kienle,et al.  Decrypting the structure of major histocompatibility complex class I- restricted cytotoxic T lymphocyte epitopes with complex peptide libraries , 1995, The Journal of experimental medicine.

[145]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[146]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[147]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[148]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[149]  S. Rosenberg,et al.  T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy , 2013, Proceedings of the National Academy of Sciences.

[150]  M. Quigley,et al.  CD4 T Cells Are Required for CD8 T Cell Survival during Both Primary and Memory Recall Responses1 , 2007, The Journal of Immunology.

[151]  B. Baker,et al.  Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics. , 2010, Molecular immunology.

[152]  H. Sugiyama,et al.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.

[153]  T. Blankenstein,et al.  A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer , 2008, Proceedings of the National Academy of Sciences.

[154]  Mark M Davis,et al.  T cell killing does not require the formation of a stable mature immunological synapse , 2004, Nature Immunology.

[155]  P. Muranski,et al.  Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma , 2010, The Journal of experimental medicine.

[156]  George F. Gao,et al.  Molecular coordination of αβ T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands , 2002 .

[157]  David M. Kranz,et al.  TCRs with high affinity for foreign pMHC show self-reactivity , 2003, Nature Immunology.

[158]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[159]  D. Kranz,et al.  Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses , 2012, Gene Therapy.

[160]  David M Kranz,et al.  Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. , 2003, Immunity.

[161]  J. Wolchok,et al.  At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy , 2013, Journal of leukocyte biology.

[162]  Jianzhu Chen,et al.  The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness1 , 2009, The Journal of Immunology.

[163]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[164]  P. Ohashi,et al.  Immunological perspective of self versus tumor antigens: insights from the RIP‐gp model , 2011, Immunological reviews.

[165]  L. K. Ely,et al.  Antagonism of Antiviral and Allogeneic Activity of a Human Public CTL Clonotype by a Single Altered Peptide Ligand: Implications for Allograft Rejection 1 , 2005, The Journal of Immunology.

[166]  K. Garcia,et al.  How a Single T Cell Receptor Recognizes Both Self and Foreign MHC , 2007, Cell.

[167]  L R Pease,et al.  Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. , 1998, Science.

[168]  D. Sherman,et al.  Immunoprecipitation of cell surface structures of cloned cytotoxic T lymphocytes by clone-specific antisera. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[169]  M. Lotze,et al.  Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[170]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[171]  A. Sewell,et al.  Soluble T cell receptors: novel immunotherapies. , 2005, Current opinion in pharmacology.